about
A human-Tetrahymena pseudoknot chimeric telomerase RNA reconstitutes a nonprocessive enzyme in vitro that is defective in telomere elongationTelomere biology: Rationale for diagnostics and therapeutics in cancerTelomerase Regulation from Beginning to the EndAn anchor site-type defect in human telomerase that disrupts telomere length maintenance and cellular immortalizationTelomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.Telomerase can act as a template- and RNA-independent terminal transferase.The product of the survival of motor neuron (SMN) gene is a human telomerase-associated protein.Telomeric recombination induced by dysfunctional telomeres.The structure and function of telomerase reverse transcriptase.Targeting human telomerase in cancer therapy.A novel somatic mutation in ACD induces telomere lengthening and apoptosis resistance in leukemia cellsThe Insertion in Fingers Domain in Human Telomerase Can Mediate Enzyme Processivity and Telomerase Recruitment to Telomeres in a TPP1-Dependent Manner.Multiple Mechanisms Contribute to the Cell Growth Defects Imparted by Human Telomerase Insertion in Fingers Domain Mutations Associated with Premature Aging Diseases.A translocation-defective telomerase with low levels of activity and processivity stabilizes short telomeres and confers immortalization.Harnessing telomerase in cancer therapeutics.Telomerase, senescence and ageing.Humanized telomeres and an attempt to express a functional human telomerase in yeast.An intact putative mouse telomerase essential N-terminal domain is necessary for proper telomere maintenance.Platinum(II) phenanthroimidazole G-quadruplex ligand induces selective telomere shortening in A549 cancer cells.Inactive C-terminal telomerase reverse transcriptase insertion splicing variants are dominant-negative inhibitors of telomerase.Platinum(II) phenanthroimidazoles for targeting telomeric G-quadruplexes.Functional multimerization of human telomerase requires an RNA interaction domain in the N terminus of the catalytic subunit.Telomeric function of mammalian telomerases at short telomeres.The C terminus of the human telomerase reverse transcriptase is a determinant of enzyme processivity.Growth defects in mouse telomerase RNA-deficient cells expressing a template-mutated mouse telomerase RNA.Telomerase inhibition in a mouse cell line with long telomeres leads to rapid telomerase reactivation.Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells.A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT.Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment.Telomerase RNA mutated in autosomal dyskeratosis congenita reconstitutes a weakly active telomerase enzyme defective in telomere elongation.Human telomerase catalyzes nucleolytic primer cleavage.Functional organization of repeat addition processivity and DNA synthesis determinants in the human telomerase multimer.Zscan4 Inhibits Maintenance DNA Methylation to Facilitate Telomere Elongation in Mouse Embryonic Stem Cells.Regulation of 5' template usage and incorporation of noncognate nucleotides by human telomerase.POT of gold: modeling dyskeratosis congenita in the mouse.Dyskeratosis congenita mutations in dyskerin SUMOylation consensus sites lead to impaired telomerase RNA accumulation and telomere defects.Regulation of telomere length and homeostasis by telomerase enzyme processivity.A platinum supramolecular square as an effective G-quadruplex binder and telomerase inhibitor.ALTered telomeres in response to telomere dysfunction.Telomerase and neuronal marker status of differentiated NT2 and SK-N-SH human neuronal cells and primary human neurons.
P50
Q24817124-B84E0A16-041C-4219-B2B6-29DBF3250AFFQ26796323-F8D56F2B-5C6F-43B2-BFA3-C4BD4057E269Q28075938-FECAC269-C44E-4C8D-8F78-D955C09174A3Q28116246-CD0D93A6-D0B1-49CE-B59C-5DBF86B25A90Q31125909-1CD983CD-A76A-48A7-BACF-5760B3B01F6FQ33895952-3E61B721-AE39-4EF4-8479-8A93186FCB5FQ34060945-3E8BAAF4-F92F-4AC1-8941-B19B7A03CEC9Q34489869-9357D92D-45FD-4029-B02C-99CB0DCFE8A7Q34535163-F062B150-C97C-4097-8D99-31A3AE176DCBQ35100460-BC1F16B3-97E3-4198-9BBA-C0ABE6FAF1C3Q35765789-728EAC19-DE0D-41C0-8E91-569586706460Q35822280-8BCAB4A7-A6FB-4A63-8871-61438558AB5DQ35926634-B4235F1D-0895-4CDD-9732-547F0CA2ED66Q36803215-C33F950B-A6A5-41F5-A08D-FCE659BD9051Q36881498-A47FF801-9522-48BE-AC5B-99885B33715DQ37063677-18F412F8-48F1-49E6-A5C4-FC9D69C44A92Q37521080-BDC7D705-E276-49FC-BDB5-44C9A4F6B4CDQ38801561-FBBC4F9E-007E-454D-9C4F-AE279D8AA2F9Q38807101-F7F7DF25-F2AE-4B00-AA17-E337BCA07773Q39035446-98DC42BD-39D9-40D4-AA12-A5F879A93E57Q39448209-2A9F7F81-E768-4730-ACA8-85B9F30EE612Q39677546-DE85043F-D7AF-409C-AE45-B7416BEF5362Q39709770-F50E8ED0-F429-4DDD-9B15-B4D1928D2861Q39792077-CDDF78A0-0675-4C98-B493-A0761E1D5E00Q39908955-32EE2A4F-5695-4695-8144-E484A6B5F283Q40037721-1A6C5CE9-0087-4ACE-A594-DB6CD4A9386FQ40246796-1118F2DA-F34B-406D-A4EF-2C1017A825D1Q40382157-A1E396EC-6C3E-4B01-93C6-10C8FEAF1132Q40412924-B7E8FA2C-1E64-4BB0-B855-1D39D5663D39Q40449336-180FE57B-333A-45C3-83C8-E2254E011F75Q40564707-15B6B34F-7FB1-4189-903B-7247E3C64707Q40763366-845877B6-F3FB-4E59-9511-706D631F04F2Q41226576-898C712A-DED5-47AC-8CF6-011CA11CB979Q41916619-41170796-6419-47C6-8848-3F42465EEF56Q42535894-7BA74016-E002-46A1-9F33-B875A4583B92Q45848125-741003BC-70BA-4C4D-A58C-29AF14F7510DQ46201651-CB59CA30-0F6E-4491-941C-1DF925E976E3Q46491611-EC518AA1-C62E-44C2-A8C9-B093ECF6398DQ53207595-36B9DD8C-ED4E-43BB-9807-DD19E5E56DCFQ54573491-7DCBD62A-1F5F-40A5-BBAB-14A78EF57BD5
P50
name
Chantal Autexier
@ast
Chantal Autexier
@en
Chantal Autexier
@es
Chantal Autexier
@nl
type
label
Chantal Autexier
@ast
Chantal Autexier
@en
Chantal Autexier
@es
Chantal Autexier
@nl
prefLabel
Chantal Autexier
@ast
Chantal Autexier
@en
Chantal Autexier
@es
Chantal Autexier
@nl
P214
P244
P214
P244
n2011185397
P31
P7859
lccn-n2011185397